B
Beatriz Serrano
Researcher at University of Barcelona
Publications - 21
Citations - 1683
Beatriz Serrano is an academic researcher from University of Barcelona. The author has contributed to research in topics: Cervical cancer & Cancer. The author has an hindex of 12, co-authored 18 publications receiving 1335 citations.
Papers
More filters
Journal ArticleDOI
Comprehensive control of human papillomavirus infections and related diseases.
F. Xavier Bosch,Thomas R. Broker,David Forman,Anna-Barbara Moscicki,Maura L. Gillison,John Doorbar,Peter L. Stern,Margaret Stanley,Marc Arbyn,Mario Poljak,Jack Cuzick,Philip E. Castle,John T. Schiller,Lauri E. Markowitz,William A. Fisher,Karen Canfell,Lynette Denny,Eduardo L. Franco,Marc Steben,Mark A. Kane,Mark Schiffman,Chris J.L.M. Meijer,Rengaswamy Sankaranarayanan,Xavier Castellsagué,Jane J. Kim,Maria Brotons,Laia Alemany,Ginesa Albero,Mireia Diaz,Silvia de Sanjosé,Ahti Anttila,Lawrence Banks,Christine Bergeron,Jerome L. Belinson,Johannes Berkhof,Ignacio G. Bravo,Freddie Bray,Julia M.L. Brotherton,Laia Bruni,Ann N. Burchell,Anil K. Chaturvedi,Harrell W. Chesson,Myriam Chevarie-Davis,Heather Cubie,Shelley L. Deeks,Catherine de Martel,Joakim Dillner,Mark H. Einstein,Jacques Ferlay,Alison Nina Fiander,Silvia Franceschi,Suzanne M. Garland,Anna R. Giuliano,Marc T. Goodman,Patti E. Gravitt,Ian N. Hampson,Isabelle Heard,Thomas Iftner,Sandra D. Isidean,Christina Jensen,Jose Jeronimo,Walter Kinney,Henry C Kitchener,Susanne K. Kjaer,Boŝtjan J. Kocjan,George Koliopoulos,Shalini L Kulasingam,Charles J.N. Lacey,D. Scott LaMontagne,Eduardo Lazcano-Ponce,Attila T. Lorincz,Joannie Lortet-Tieulent,Pontus Naucler,Gina Ogilvie,Joel M. Palefsky,Julian Peto,Ligia A. Pinto,Martyn Plummer,You-Lin Qiao,Wim Quint,Guglielmo Ronco,Steve Schwartz,Beatriz Serrano,Jennifer S. Smith,Peter J.F. Snijders,Isabelle Soerjomataram,Bettie M. Steinberg,Mark H. Stoler,Anne Szarewski,Connie Trimble,Vivien Tsu,Pierre Van Damme,Sjoerd H. van der Burg,Andrea Vicari,Jérôme Vignat,Magnus von Knebel Doeberitz,Alex Vorsters,Susan A. Wang,Scott Wittet +98 more
TL;DR: There must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries.
Journal ArticleDOI
Epidemiology and burden of HPV-related disease.
TL;DR: The latest estimates of the global burden of HPV-related diseases, trends, the attributable fraction by HPV types, and the potential preventative fraction are summarized.
Journal ArticleDOI
Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
Beatriz Serrano,Laia Alemany,Sara Tous,Laia Bruni,Gary M. Clifford,Thomas W. Weiss,Francesc Bosch,Silvia de Sanjosé +7 more
TL;DR: The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide and if the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.
Journal ArticleDOI
Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report.
S de Sanjosé,Beatriz Serrano,Xavier Castellsagué,Maria Brotons,J. Muñoz,Laia Bruni,Franz X. Bosch +6 more
Journal ArticleDOI
Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions
Beatriz Serrano,Silvia de Sanjosé,Sara Tous,Beatriz Quirós,Nubia Muñoz,Xavier Bosch,Laia Alemany +6 more
TL;DR: The addition of HPVs 31/33/45/52/58 to HPV types included in current vaccines (HPV16/18) could prevent almost 90% of HPV positive female anogenital lesions worldwide and take into account that most HPV-related cancers are ICC ones, the 9-valent HPV vaccine could potentially avoid almost 88% of all female anogenic cancers.